查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1989030

2034年情緒生物標記人工智慧市場預測－全球分析（按生物標記類型、組成部分、部署模式、技術、應用、最終用戶和地區分類）

Emotional Biomarker AI Market Forecasts to 2034 - Global Analysis By Biomarker Type, Component, Deployment Mode, Technology, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球情緒生物標記 AI 市場預計將在 2026 年達到 51 億美元，並在預測期內以 14.6% 的複合年成長率成長，到 2034 年達到 152 億美元。

情緒生物標記人工智慧是指透過偵測和分析生理及行為訊號（例如臉部表情、語音模式、心率變異性、皮膚電導率和神經活動）來識別和分析情緒狀態的人工智慧系統。這些平台處理多模態資料流，即時或透過儲存記錄推斷情緒反應，從而應用於心理健康護理、消費者體驗研究、人機互動和職場健康等領域。透過將微妙的生物和行為徵兆轉化為可操作的情緒智慧，情緒生物標記人工智慧為臨床醫生、研究人員和企業開闢了理解人類的新維度。

對心理健康和保健技術的需求日益成長

全球對心理健康作為公共衛生優先事項的認知不斷提高，加上對技術驅動的健康監測工具的需求日益成長，正推動著臨床、消費和企業市場對情緒生物標記人工智慧平台的投資。醫療保健機構正在尋求客觀、持續測量情緒狀態的方法，以補充傳統的臨床評估，並改善心理健康診斷和治療監測。同時，消費科技公司將情緒智商視為人機互動領域的下一個前沿領域。

情緒監測引發的倫理問題

引入能夠持續分析和解讀個體生理及行為訊號所反映的情緒狀態的系統，引發了關於知情同意、情緒隱私以及情緒資料潛在操縱等方面的嚴重倫理問題。科技能夠在個體完全不知情的情況下推斷其內在情緒並據此採取行動，這種理念挑戰了根深蒂固的個人自主權觀念。批評者認為，商業化的情緒人工智慧系統可能會產生不準確的推理，如果用於關鍵決策，就會帶來風險。

數位健康監測領域的應用不斷擴展

數位健康監測平台、遠端醫療服務和遠端患者監護計畫的快速發展，為情緒生物標記人工智慧（AI）技術的整合創造了極其寶貴的機會。心理健康臨床醫生越來越需要連續、客觀的生物標記數據，以補充患者的主觀自我報告，並實現更及時的治療調整。將情緒生物標記AI技術整合到遠端監測平台中，可以為臨床醫生提供縱向情緒軌跡數據，揭示兩次治療之間的病情惡化和好轉情況，從而支持更快速、更個人化的照護。

缺乏情感人工智慧的監管標準

目前，大多數司法管轄區在情緒人工智慧領域缺乏全面的法規結構，導致在可接受的應用場景、所需的準確性標準、資料處理義務以及錯誤情緒推斷的責任認定等方面存在諸多不確定性。歐洲及其他地區的資料保護機構正在積極考慮採取監管措施。缺乏檢驗的標準化生物標記通訊協定引發了人們對科學可靠性的擔憂，並可能限制其臨床應用；而無法證明其系統具有可重複準確性的供應商則面臨聲譽風險。

新冠疫情的影響：

新冠疫情對情緒生物標記人工智慧市場產生了重大影響，加速了其在醫療保健和健康領域的應用。封鎖措施和日益嚴峻的心理健康挑戰催生了對人工智慧驅動的情緒監測工具的迫切需求。各機構尋求擴充性的解決方案，以遠端評估壓力、焦慮和情緒健康狀況，從而推動了生物標記和預測分析領域的創新。儘管供應鏈中斷最初延緩了硬體整合，但人們對情緒健康的日益關注使人工智慧生物標記成為後疫情時代醫療保健戰略的關鍵要素，並最終產生了積極的長期影響。

在預測期內，臉部表情分析細分市場預計將成為規模最大的細分市場。

臉部表情分析領域在情緒生物標記人工智慧市場中佔據最大佔有率。電腦視覺技術能夠從視訊串流中偵測細微的臉部和情緒線索，是目前最成熟、商業性化應用最廣泛的情緒人工智慧技術之一。其應用範圍涵蓋市場調查、心理健康篩檢、客戶體驗分析以及教育領域的參與度監測等。基於攝影機的系統的普及、廣泛的商業性需求以及與數位通訊平台日益增強的融合，都鞏固了該領域的市場主導地位。

預計在預測期內，軟體產業將錄得最高的複合年成長率。

預計在情緒生物標記人工智慧市場中，軟體板塊將實現最高的複合年成長率。能夠處理和解讀多模態情緒資料的AI分析引擎是情緒AI平台中最有價值的組成部分。隨著透過雲端交付的情緒智慧服務擴展到醫療保健、客戶體驗和企業健康管理市場，軟體訂閱收入正在加速成長。情緒AI API與現有業務和臨床應用的日益融合，進一步推動了軟體需求的成長，其成長速度超過了硬體和服務。

市佔率最大的地區：

在整個預測期內，北美預計將保持最大的市場佔有率，這得益於其先進的醫療保健基礎設施、對人工智慧研究的大力投入以及數位健康技術的廣泛應用。該地區受益於人們對心理健康問題的高度關注、政府的支持性舉措以及科技公司與醫療保健提供者之間的合作。此外，領先的人工智慧公司和Start-Ups的存在正在加速情緒生物標記解決方案的創新，確保北美繼續保持市場成長中心的地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於技術的快速普及、醫療保健支出的成長以及人們對情緒健康的日益關注。中國、印度和日本等國家正在大力投資人工智慧驅動的醫療保健解決方案，並得到了不斷擴展的數位生態系統和政府措施的支持。都市區壓力水平的上升以及情緒生物標記人工智慧技術在遠端醫療平台中的應用，進一步推動了市場需求，使亞太地區成為該市場成長最快的地區。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章：全球情緒生物標記人工智慧市場：依生物標記類型分類

  • 臉部表情分析
  • 語音語調分析
  • 生理訊號
    • 心率變異性
    • 皮膚電導率
  • 眼動追蹤
  • 神經活動模式
  • 多模態生物標記物

第6章 全球情緒生物標記人工智慧市場：按組件分類

  • 軟體
  • 硬體
  • 服務

第7章：全球情緒生物標記人工智慧市場：依部署模式分類

  • 現場
  • 基於雲端的

第8章：全球情緒生物標記人工智慧市場：按技術分類

  • 機器學習
  • 電腦視覺
  • 自然語言處理
  • 穿戴式裝置整合

第9章 全球情緒生物標記人工智慧市場：按應用領域分類

  • 心理健康監測
  • 客戶經驗分析
  • 市場研究
  • 醫療診斷
  • 汽車安全系統

第10章 全球情緒生物標記人工智慧市場：按最終用戶分類

  • 醫療服務提供方
  • 公司
  • 研究機構
  • 汽車製造商
  • 學術機構

第11章 全球情緒生物標記人工智慧市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • IBM Corporation
  • Microsoft Corporation
  • Google LLC
  • Amazon Web Services, Inc.
  • Apple Inc.
  • Samsung Electronics Co., Ltd.
  • Philips NV
  • Medtronic plc
  • Siemens Healthineers AG
  • Honeywell International Inc.
  • Oracle Corporation
  • Affectiva（Smart Eye AB）
  • Realeyes OU
  • Beyond Verbal
  • Thales Group
  • Lockheed Martin Corporation
  • Northrop Grumman Corporation
  • C3.ai, Inc.
Product Code: SMRC34319

According to Stratistics MRC, the Global Emotional Biomarker AI Market is accounted for $5.1 billion in 2026 and is expected to reach $15.2 billion by 2034 growing at a CAGR of 14.6% during the forecast period. Emotional biomarker AI refers to artificial intelligence systems that detect and analyze emotional states through physiological and behavioral signals including facial expressions, voice patterns, heart rate variability, skin conductance, and neural activity. These platforms process multimodal data streams to infer emotional responses in real time or through stored recordings, enabling applications in mental health care, consumer experience research, human-computer interaction, and workplace wellness. By translating subtle biological and behavioral cues into actionable emotional intelligence, emotional biomarker AI unlocks new dimensions of human understanding for clinicians, researchers, and businesses.

Market Dynamics:

Driver:

Growing mental health and wellness technology demand

Increasing global awareness of mental health as a public health priority, combined with growing demand for technology-enabled wellness monitoring tools, is driving investment in emotional biomarker AI platforms across clinical, consumer, and enterprise markets. Healthcare providers seek objective continuous measures of emotional state to supplement traditional clinical assessments and improve mental health diagnosis and treatment monitoring. Consumer technology companies see emotional intelligence as a next frontier in human-computer interaction.

Restraint:

Ethical concerns over emotional surveillance

Deployment of systems that continuously analyze and interpret an individual's emotional states from physiological and behavioral signals raises profound ethical concerns about informed consent, emotional privacy, and potential for manipulation of emotional data. The idea that technology can infer and act upon an individual's inner emotional life without their full understanding challenges deeply held notions of personal autonomy. Critics argue commercial emotion AI systems may produce inaccurate inferences used to make consequential decisions, creating risks.

Opportunity:

Expanding applications in digital health monitoring

The rapid expansion of digital health monitoring platforms, telehealth services, and remote patient monitoring programs is creating high-value integration opportunities for emotional biomarker AI capabilities. Mental health clinicians increasingly seek continuous, objective biomarker data that supplements subjective patient self-report and enables more timely therapeutic adjustments. Emotional biomarker AI embedded in remote monitoring platforms can provide clinicians with longitudinal emotional trend data that reveals deterioration or improvement between sessions, supporting more responsive and personalized care.

Threat:

Lack of regulatory standards for emotion AI

The emotional AI field currently operates without a comprehensive regulatory framework in most jurisdictions, creating significant uncertainty about permissible use cases, required accuracy standards, data handling obligations, and liability for erroneous emotional inferences. Regulatory intervention is actively being considered by data protection authorities in Europe and elsewhere. Absence of validated standardized biomarker protocols raises scientific credibility concerns that may limit clinical adoption and create reputational risks for vendors whose systems fail to demonstrate reproducible accuracy.

Covid-19 Impact:

The Covid-19 pandemic significantly influenced the Emotional Biomarker AI Market, accelerating adoption across healthcare and wellness sectors. Lockdowns and rising mental health challenges created urgent demand for AI-driven emotional monitoring tools. Organizations sought scalable solutions to assess stress, anxiety, and emotional well-being remotely, fueling innovation in biomarkers and predictive analytics. While supply chain disruptions initially slowed hardware integration, the long-term effect was positive, as awareness of emotional health surged, positioning AI biomarkers as essential in post-pandemic healthcare strategies.

The facial expression analysis segment is expected to be the largest during the forecast period

The facial expression analysis segment holds the largest share in the emotional biomarker AI market. Computer vision technology capable of detecting micro-expressions and emotional cues from video feeds is among the most mature and commercially deployed forms of emotional AI. Its applications span market research, mental health screening, customer experience analytics, and educational engagement monitoring. The accessibility of camera-based systems, broad commercial interest, and growing integration with digital communication platforms sustain this segment's dominant market position.

The software segment is expected to have the highest CAGR during the forecast period

The software segment is expected to record the highest CAGR in the emotional biomarker AI market. AI-powered analytics engines that process and interpret multimodal emotional data form the highest-value component of emotional AI platforms. As cloud-delivered emotional intelligence services expand across healthcare, customer experience, and enterprise wellness markets, software subscription revenues are accelerating. The growing integration of emotional AI APIs into existing business and clinical applications further drives software demand at a rate surpassing hardware and services.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its advanced healthcare infrastructure, strong investment in AI research, and widespread adoption of digital health technologies. The region benefits from high awareness of mental health issues, supportive government initiatives, and collaborations between technology firms and medical institutions. Additionally, the presence of leading AI companies and startups accelerates innovation in emotional biomarker solutions, ensuring North America remains the dominant hub for market growth.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapid technological adoption, growing healthcare expenditure, and increasing awareness of emotional well-being. Countries such as China, India, and Japan are investing heavily in AI-driven healthcare solutions, supported by expanding digital ecosystems and government initiatives. Rising stress levels among urban populations and the integration of emotional biomarker AI in telemedicine platforms further drive demand, making Asia Pacific the fastest-growing region in this market.

Key players in the market

Some of the key players in Emotional Biomarker AI Market include IBM Corporation, Microsoft Corporation, Google LLC, Amazon Web Services, Inc., Apple Inc., Samsung Electronics Co., Ltd., Philips N.V., Medtronic plc, Siemens Healthineers AG, Honeywell International Inc., Oracle Corporation, Affectiva (Smart Eye AB), Realeyes OU, Beyond Verbal, Thales Group, Lockheed Martin Corporation, Northrop Grumman Corporation, and C3.ai, Inc.

Key Developments:

In February 2026, Google emphasized AI-enabled emotional biomarker technologies, projecting efficiency gains in healthcare diagnostics and consumer applications. At global summits, the company showcased demand response automation for wellness platforms, highlighting sustainability, personalization, and resilience in addressing rising emotional health challenges.

In February 2026, Apple reinforced its leadership in emotional biomarker AI, unveiling adaptive monitoring solutions integrated into wearable devices. The company demonstrated demand-responsive automation for homes and healthcare, highlighting sustainability, efficiency, and resilience in supporting personalized well-being across connected ecosystems.

In January 2026, Microsoft introduced AI-driven emotional biomarker solutions, highlighting adaptive analytics for mental health and productivity. The initiative focused on demand-responsive systems, enabling sustainable monitoring and resilience while supporting flexible deployment across homes, clinics, and industrial ecosystems globally.

Biomarker Types Covered:

  • Facial Expression Analysis
  • Voice Tone Analytics
  • Physiological Signals
  • Eye Tracking
  • Neural Activity Patterns
  • Multimodal Biomarkers

Components Covered:

  • Software
  • Hardware
  • Services

Deployment Modes Covered:

  • On-Premise
  • Cloud-Based

Technologies Covered:

  • Machine Learning
  • Computer Vision
  • Natural Language Processing
  • Wearable Integration

Applications Covered:

  • Mental Health Monitoring
  • Customer Experience Analytics
  • Market Research
  • Healthcare Diagnostics
  • Automotive Safety Systems

End Users Covered:

  • Healthcare Providers
  • Enterprises
  • Research Institutes
  • Automotive Companies
  • Academic Institutions

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Emotional Biomarker AI Market, By Biomarker Type

  • 5.1 Facial Expression Analysis
  • 5.2 Voice Tone Analytics
  • 5.3 Physiological Signals
    • 5.3.1 Heart Rate Variability
    • 5.3.2 Skin Conductance
  • 5.4 Eye Tracking
  • 5.5 Neural Activity Patterns
  • 5.6 Multimodal Biomarkers

6 Global Emotional Biomarker AI Market, By Component

  • 6.1 Software
  • 6.2 Hardware
  • 6.3 Services

7 Global Emotional Biomarker AI Market, By Deployment Mode

  • 7.1 On-Premise
  • 7.2 Cloud-Based

8 Global Emotional Biomarker AI Market, By Technology

  • 8.1 Machine Learning
  • 8.2 Computer Vision
  • 8.3 Natural Language Processing
  • 8.4 Wearable Integration

9 Global Emotional Biomarker AI Market, By Application

  • 9.1 Mental Health Monitoring
  • 9.2 Customer Experience Analytics
  • 9.3 Market Research
  • 9.4 Healthcare Diagnostics
  • 9.5 Automotive Safety Systems

10 Global Emotional Biomarker AI Market, By End User

  • 10.1 Healthcare Providers
  • 10.2 Enterprises
  • 10.3 Research Institutes
  • 10.4 Automotive Companies
  • 10.5 Academic Institutions

11 Global Emotional Biomarker AI Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 IBM Corporation
  • 14.2 Microsoft Corporation
  • 14.3 Google LLC
  • 14.4 Amazon Web Services, Inc.
  • 14.5 Apple Inc.
  • 14.6 Samsung Electronics Co., Ltd.
  • 14.7 Philips N.V.
  • 14.8 Medtronic plc
  • 14.9 Siemens Healthineers AG
  • 14.10 Honeywell International Inc.
  • 14.11 Oracle Corporation
  • 14.12 Affectiva (Smart Eye AB)
  • 14.13 Realeyes OU
  • 14.14 Beyond Verbal
  • 14.15 Thales Group
  • 14.16 Lockheed Martin Corporation
  • 14.17 Northrop Grumman Corporation
  • 14.18 C3.ai, Inc.

List of Tables

  • Table 1 Global Emotional Biomarker AI Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Emotional Biomarker AI Market Outlook, By Biomarker Type (2023-2034) ($MN)
  • Table 3 Global Emotional Biomarker AI Market Outlook, By Facial Expression Analysis (2023-2034) ($MN)
  • Table 4 Global Emotional Biomarker AI Market Outlook, By Voice Tone Analytics (2023-2034) ($MN)
  • Table 5 Global Emotional Biomarker AI Market Outlook, By Physiological Signals (2023-2034) ($MN)
  • Table 6 Global Emotional Biomarker AI Market Outlook, By Heart Rate Variability (2023-2034) ($MN)
  • Table 7 Global Emotional Biomarker AI Market Outlook, By Skin Conductance (2023-2034) ($MN)
  • Table 8 Global Emotional Biomarker AI Market Outlook, By Eye Tracking (2023-2034) ($MN)
  • Table 9 Global Emotional Biomarker AI Market Outlook, By Neural Activity Patterns (2023-2034) ($MN)
  • Table 10 Global Emotional Biomarker AI Market Outlook, By Multimodal Biomarkers (2023-2034) ($MN)
  • Table 11 Global Emotional Biomarker AI Market Outlook, By Component (2023-2034) ($MN)
  • Table 12 Global Emotional Biomarker AI Market Outlook, By Software (2023-2034) ($MN)
  • Table 13 Global Emotional Biomarker AI Market Outlook, By Hardware (2023-2034) ($MN)
  • Table 14 Global Emotional Biomarker AI Market Outlook, By Services (2023-2034) ($MN)
  • Table 15 Global Emotional Biomarker AI Market Outlook, By Deployment Mode (2023-2034) ($MN)
  • Table 16 Global Emotional Biomarker AI Market Outlook, By On-Premise (2023-2034) ($MN)
  • Table 17 Global Emotional Biomarker AI Market Outlook, By Cloud-Based (2023-2034) ($MN)
  • Table 18 Global Emotional Biomarker AI Market Outlook, By Technology (2023-2034) ($MN)
  • Table 19 Global Emotional Biomarker AI Market Outlook, By Machine Learning (2023-2034) ($MN)
  • Table 20 Global Emotional Biomarker AI Market Outlook, By Computer Vision (2023-2034) ($MN)
  • Table 21 Global Emotional Biomarker AI Market Outlook, By Natural Language Processing (2023-2034) ($MN)
  • Table 22 Global Emotional Biomarker AI Market Outlook, By Wearable Integration (2023-2034) ($MN)
  • Table 23 Global Emotional Biomarker AI Market Outlook, By Application (2023-2034) ($MN)
  • Table 24 Global Emotional Biomarker AI Market Outlook, By Mental Health Monitoring (2023-2034) ($MN)
  • Table 25 Global Emotional Biomarker AI Market Outlook, By Customer Experience Analytics (2023-2034) ($MN)
  • Table 26 Global Emotional Biomarker AI Market Outlook, By Market Research (2023-2034) ($MN)
  • Table 27 Global Emotional Biomarker AI Market Outlook, By Healthcare Diagnostics (2023-2034) ($MN)
  • Table 28 Global Emotional Biomarker AI Market Outlook, By Automotive Safety Systems (2023-2034) ($MN)
  • Table 29 Global Emotional Biomarker AI Market Outlook, By End User (2023-2034) ($MN)
  • Table 30 Global Emotional Biomarker AI Market Outlook, By Healthcare Providers (2023-2034) ($MN)
  • Table 31 Global Emotional Biomarker AI Market Outlook, By Enterprises (2023-2034) ($MN)
  • Table 32 Global Emotional Biomarker AI Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 33 Global Emotional Biomarker AI Market Outlook, By Automotive Companies (2023-2034) ($MN)
  • Table 34 Global Emotional Biomarker AI Market Outlook, By Academic Institutions (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.